News | April 14, 2026
Roche wins CE mark for blood-based MS brain damage test
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Paves the way for next-gen ultra-precise gas sensing
A major push to sharpen the future of cancer treatment is underway
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Subscribe To Our Newsletter & Stay Updated
